In this blog post, Mark Jones speaks with Romina Tocci, Senior Laboratory Manager in the ICR’s Centre for Cancer Drug Discovery, about what this technology means for our ability to discover new cancer ...

Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

Professor Pearl's group seeks to understand the structural basis for assembly, specificity and regulation of the multi-protein complexes involved in the recognition, repair and signalling of DNA ...

Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer. The findings, published in Nature, show that blocking the ...

These days, in the era of personalised medicine, whenever researchers discover a new cancer drug they are expected to show exactly how it works and to prove that it is exerting its therapeutic effect ...

Twenty years ago today, the International Genome Sequencing Consortium published the first detailed analysis of the human genome. The paper appeared online in Nature on 15 February 2001, followed by a ...

Darwinian evolution has influenced and inspired the rapidly growing field of evolutionary medicine that uses evolution to approach the diagnosis, treatment, and prevention of human diseases. Cancer ...

Image: a woman walks her dog. Regular leisure time physical activity may reduce the risk of breast cancer for women before menopause, according to new research funded by Breast Cancer Now. The ...

A promising new therapy can help patients with aggressive advanced breast cancer live longer and delay the need for further chemotherapy, new research has shown. The international study, funded by ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for a rare form of ovarian cancer by the US regulatory body the Food and Drug Administration (FDA) ...